ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0977

Prevalence of Arthritis in the United States: National Estimates from a Population-based Study

Sumanth Chandrupatla1, Kranti Rumalla2 and Jasvinder Singh1, 1University of Alabama at Birmingham, Birmingham, AL, 2Northwestern School of Medicine, Chicago, IL

Meeting: ACR Convergence 2023

Keywords: Epidemiology, Outcome measures, population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0965–0992) Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Arthritis is the number 1 cause of disability among U.S. adults and reported to cost > $300 billion in direct and indirect costs in 2013. Theis et al. found that the prevalence of arthritis in the US grew from 54.4 million in 2013-2015 to 58.5 million in 2016-2018. These estimates were derived from the U.S. CDC National Health Interview Survey (NHIS), which has recently undergone a total redesign. With the updated NHIS, we aimed to query an updated nationally-representative estimate of the prevalence and burden of arthritis in the U.S. adult population.

Methods: We identified patients over the age of 18 years in the 2019 and 2021 National Health Interview Survey (NHIS) who had doctor-diagnosed arthritis (n=15,822; 21.3%; excluded 2020 due to unclear impact of COVID-19 on NHIS completion). Sampling weights were used to create nationally representative estimates. Unadjusted and age-standardized estimates of arthritis prevalence were generated. Sociodemographic and health characteristics were analyzed. We compared with previous years’ prevalence estimates.

Results: During 2019 and 2021, an estimated 53.7 million people over the age of 18 had arthritis (21.3%; 18.8% age-standardized; Table 1). This represents a 5 million person decrease from 2016-2018 (58.5 million; Figure 1), but is similar to the estimates from 2013-2015 (54.4 million; Figure 1). Arthritis prevalence was greater than 50% in adults with ≥3 ADL limitations (65.2%; Table 1) and adults with 2 IADL limitations (50.2%; Table 1). Arthritis was most prevalent in adults aged ≥65 years (47.6%), non-Hispanic whites (24.9%), adults unable to work or disabled (49.5), and adults who reported fair or poor health (48.9%)

Conclusion: Arthritis has significant impact on disability and functional limitation in US adults. Surprisingly, we found stabilization of arthritis prevalence in the U.S. from the 2019 and 2021 national estimates rather than an anticipated increase. Stratified analyses by age, sex, and other demographic characteristics need to be performed to understand as to which subgroup accounts for this recent stabilization/decrease in arthritis prevalence.

Supporting image 1

Supporting image 2


Disclosures: S. Chandrupatla: None; K. Rumalla: None; J. Singh: Other, 2, 6, 11, 11, 12, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix, Charlotte’s Web, 12, Atai life sciences, kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, 12, speaker’s bureau of Simply Speaking, other, 12, received institutional research support from Zimmer Biomet Holdings. JAS received food and beverage payments from Intuitive Surgical Inc./Philips Elec, Other, 12, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam.

To cite this abstract in AMA style:

Chandrupatla S, Rumalla K, Singh J. Prevalence of Arthritis in the United States: National Estimates from a Population-based Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-arthritis-in-the-united-states-national-estimates-from-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-arthritis-in-the-united-states-national-estimates-from-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology